Please enable JavaScript to continue using this application.

Compare $LCTX vs $QTTB | Chartloom

Compare

$LCTX vs $QTTB

Lineage Cell Therapeutics Inc · Q32 Bio Inc

LCTX

Lineage Cell Therapeutics Inc

QTTB

Q32 Bio Inc

Compare $LCTX vs $QTTB

Comparing Lineage Cell Therapeutics Inc and Q32 Bio Inc

LCTXLineage Cell Therapeutics Inc

QTTBQ32 Bio Inc

LCTXLineage Cell Therapeutics Inc

Market cap

$248M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

28.49x

Rev growth (TTM)

-37.1%

YTD performance

-39.4%

52W performance

-42.5%

FCF yield

-10.0%

QTTBQ32 Bio Inc

Market cap

$248M

P/E (TTM)

8.22x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

142.4%

52W performance

178.9%

FCF yield

-8.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

LCTX

QTTB

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

QTTB

Q32 Bio Inc

Market Cap

LCTX$248M

QTTB$248M

Enterprise Value

LCTX$210M

QTTB$142M

Price

LCTX$0.99

QTTB$8.34

P/E Ratio

LCTXN/A

QTTB8.22x

P/S Ratio

LCTX18.94x

QTTB4.62x

EV/Sales

LCTX16.09x

QTTB2.64x

EV/EBITDA

LCTX0.00x

QTTB3.69x

P/B Ratio

LCTX3.86x

QTTB2.31x

P/FCF Ratio

LCTXN/A

QTTBN/A

EV/FCF

LCTX-8.48x

QTTB-7.16x

PEG Ratio

LCTXN/A

QTTBN/A

Forward P/E (NTM)

LCTXN/A

QTTBN/A

Forward P/S (NTM)

LCTX28.49x

QTTBN/A

Revenue (TTM)

LCTX$13M

QTTB$54M

Revenue Growth (YoY)

LCTX-37.1%

QTTBN/A

Forward Rev Growth

LCTX-16.6%

QTTB215.1%

Gross Margin (TTM)

LCTX94.1%

QTTB0.0%

Operating Margin (TTM)

LCTX0.0%

QTTB85.4%

EBITDA Margin (TTM)

LCTX-199.6%

QTTB71.6%

Net Margin (TTM)

LCTX-246.6%

QTTB93.7%

FCF Margin (TTM)

LCTX-189.7%

QTTB-36.9%

Net Income (TTM)

LCTX$-32M

QTTB$50M

FCF (TTM)

LCTX$-25M

QTTB$-20M

EPS (TTM)

LCTX-$0.13

QTTB$0.00

ROE (TTM)

LCTX-7114.0%

QTTB137.4%

ROA (TTM)

LCTX-3087.0%

QTTB45.1%

ROIC (TTM)

LCTX-7104.0%

QTTB111.6%

Cash

LCTX$37M

QTTB$106M

Debt

LCTX$48K

QTTB$0

Net Cash/Debt

LCTX$37M

QTTB$106M

Current Ratio (TTM)

LCTX6.61x

QTTB20.30x

Quick Ratio (TTM)

LCTX6.44x

QTTB19.80x

Debt/Equity (TTM)

LCTX0.00x

QTTB2.29x

Debt/Assets (TTM)

LCTX0.0%

QTTB0.0%

Interest Coverage (TTM)

LCTXN/A

QTTBN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

QTTB0.00x

Beta

LCTX1.67

QTTB0.50

52W Performance

LCTX-42.5%

QTTB178.9%

YTD Performance

LCTX-39.4%

QTTB142.4%

% from 52W High

LCTX-52.4%

QTTB-64.6%

% from 52W Low

LCTX12.7%

QTTB337.8%

Asset Turnover (TTM)

LCTX0.07x

QTTB0.87x

FCF Yield (TTM)

LCTX-10.0%

QTTB-8.0%

Earnings Yield (TTM)

LCTX-13.0%

QTTB20.3%

Dividend Yield (TTM)

LCTXN/A

QTTBN/A

Rule of 40

LCTX-226.8

QTTB-36.9

EV/GP/RG

LCTXN/A

QTTBN/A

Ticker research

View LCTX research View QTTB research

Metric	LCTX Lineage Cell Therapeutics Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$248M	$248M
Enterprise Value	$210M	$142M
Price	$0.99	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	18.94x	4.62x
EV/Sales	16.09x	2.64x
EV/EBITDA	0.00x	3.69x
P/B Ratio	3.86x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	N/A
Revenue & Growth
Revenue (TTM)	$13M	$54M
Revenue Growth (YoY)	-37.1%	N/A
Forward Rev Growth	-16.6%	215.1%
Profitability
Gross Margin (TTM)	94.1%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-199.6%	71.6%
Net Margin (TTM)	-246.6%	93.7%
FCF Margin (TTM)	-189.7%	-36.9%
Net Income (TTM)	$-32M	$50M
FCF (TTM)	$-25M	$-20M
EPS (TTM)	-$0.13	$0.00
ROE (TTM)	-7114.0%	137.4%
ROA (TTM)	-3087.0%	45.1%
ROIC (TTM)	-7104.0%	111.6%
Financial Health
Cash	$37M	$106M
Debt	$48K	$0
Net Cash/Debt	$37M	$106M
Current Ratio (TTM)	6.61x	20.30x
Quick Ratio (TTM)	6.44x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	0.50
52W Performance	-42.5%	178.9%
YTD Performance	-39.4%	142.4%
% from 52W High	-52.4%	-64.6%
% from 52W Low	12.7%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.87x
FCF Yield (TTM)	-10.0%	-8.0%
Earnings Yield (TTM)	-13.0%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-36.9
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View QTTB research

Valuation

P/E Ratio

QTTB

8.22x

P/S Ratio

QTTB

4.62x

LCTX

18.94x

EV/FCF

LCTX

-8.48x

QTTB

-7.16x

Growth & revenue

Revenue Growth TTM

LCTX

-37.1%

Forward Revenue Growth

QTTB

215.1%

LCTX

-16.6%

Profitability & performance

Gross Margin

LCTX

94.1%

QTTB

0.0%

ROE

QTTB

137.4%

LCTX

-7114.0%

FCF Yield %

QTTB

-8.0%

LCTX

-10.0%

52-Week Performance

QTTB

178.9%

LCTX

-42.5%

Detailed metrics comparison

LCTX

Lineage Cell Therapeutics Inc

QTTB

Q32 Bio Inc

Market Cap

LCTX$248M

QTTB$248M

Enterprise Value

LCTX$210M

QTTB$142M

Price

LCTX$0.99

QTTB$8.34

P/E Ratio

LCTXN/A

QTTB8.22x

P/S Ratio

LCTX18.94x

QTTB4.62x

EV/Sales

LCTX16.09x

QTTB2.64x

EV/EBITDA

LCTX0.00x

QTTB3.69x

P/B Ratio

LCTX3.86x

QTTB2.31x

P/FCF Ratio

LCTXN/A

QTTBN/A

EV/FCF

LCTX-8.48x

QTTB-7.16x

PEG Ratio

LCTXN/A

QTTBN/A

Forward P/E (NTM)

LCTXN/A

QTTBN/A

Forward P/S (NTM)

LCTX28.49x

QTTBN/A

Revenue (TTM)

LCTX$13M

QTTB$54M

Revenue Growth (YoY)

LCTX-37.1%

QTTBN/A

Forward Rev Growth

LCTX-16.6%

QTTB215.1%

Gross Margin (TTM)

LCTX94.1%

QTTB0.0%

Operating Margin (TTM)

LCTX0.0%

QTTB85.4%

EBITDA Margin (TTM)

LCTX-199.6%

QTTB71.6%

Net Margin (TTM)

LCTX-246.6%

QTTB93.7%

FCF Margin (TTM)

LCTX-189.7%

QTTB-36.9%

Net Income (TTM)

LCTX$-32M

QTTB$50M

FCF (TTM)

LCTX$-25M

QTTB$-20M

EPS (TTM)

LCTX-$0.13

QTTB$0.00

ROE (TTM)

LCTX-7114.0%

QTTB137.4%

ROA (TTM)

LCTX-3087.0%

QTTB45.1%

ROIC (TTM)

LCTX-7104.0%

QTTB111.6%

Cash

LCTX$37M

QTTB$106M

Debt

LCTX$48K

QTTB$0

Net Cash/Debt

LCTX$37M

QTTB$106M

Current Ratio (TTM)

LCTX6.61x

QTTB20.30x

Quick Ratio (TTM)

LCTX6.44x

QTTB19.80x

Debt/Equity (TTM)

LCTX0.00x

QTTB2.29x

Debt/Assets (TTM)

LCTX0.0%

QTTB0.0%

Interest Coverage (TTM)

LCTXN/A

QTTBN/A

Net Debt/EBITDA (TTM)

LCTX0.00x

QTTB0.00x

Beta

LCTX1.67

QTTB0.50

52W Performance

LCTX-42.5%

QTTB178.9%

YTD Performance

LCTX-39.4%

QTTB142.4%

% from 52W High

LCTX-52.4%

QTTB-64.6%

% from 52W Low

LCTX12.7%

QTTB337.8%

Asset Turnover (TTM)

LCTX0.07x

QTTB0.87x

FCF Yield (TTM)

LCTX-10.0%

QTTB-8.0%

Earnings Yield (TTM)

LCTX-13.0%

QTTB20.3%

Dividend Yield (TTM)

LCTXN/A

QTTBN/A

Rule of 40

LCTX-226.8

QTTB-36.9

EV/GP/RG

LCTXN/A

QTTBN/A

Ticker research

View LCTX research View QTTB research

Metric	LCTX Lineage Cell Therapeutics Inc	QTTB Q32 Bio Inc
Market & Valuation
Market Cap	$248M	$248M
Enterprise Value	$210M	$142M
Price	$0.99	$8.34
P/E Ratio	N/A	8.22x
P/S Ratio	18.94x	4.62x
EV/Sales	16.09x	2.64x
EV/EBITDA	0.00x	3.69x
P/B Ratio	3.86x	2.31x
P/FCF Ratio	N/A	N/A
EV/FCF	-8.48x	-7.16x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	28.49x	N/A
Revenue & Growth
Revenue (TTM)	$13M	$54M
Revenue Growth (YoY)	-37.1%	N/A
Forward Rev Growth	-16.6%	215.1%
Profitability
Gross Margin (TTM)	94.1%	0.0%
Operating Margin (TTM)	0.0%	85.4%
EBITDA Margin (TTM)	-199.6%	71.6%
Net Margin (TTM)	-246.6%	93.7%
FCF Margin (TTM)	-189.7%	-36.9%
Net Income (TTM)	$-32M	$50M
FCF (TTM)	$-25M	$-20M
EPS (TTM)	-$0.13	$0.00
ROE (TTM)	-7114.0%	137.4%
ROA (TTM)	-3087.0%	45.1%
ROIC (TTM)	-7104.0%	111.6%
Financial Health
Cash	$37M	$106M
Debt	$48K	$0
Net Cash/Debt	$37M	$106M
Current Ratio (TTM)	6.61x	20.30x
Quick Ratio (TTM)	6.44x	19.80x
Debt/Equity (TTM)	0.00x	2.29x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.67	0.50
52W Performance	-42.5%	178.9%
YTD Performance	-39.4%	142.4%
% from 52W High	-52.4%	-64.6%
% from 52W Low	12.7%	337.8%
Efficiency & Yields
Asset Turnover (TTM)	0.07x	0.87x
FCF Yield (TTM)	-10.0%	-8.0%
Earnings Yield (TTM)	-13.0%	20.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-226.8	-36.9
EV/GP/RG	N/A	N/A
Ticker research	View LCTX research	View QTTB research